When stem cells meet COVID-19: recent advances, challenges and future perspectives

被引：0

作者：

Shasha Li

Hecheng Zhu

Ming Zhao

Weidong Liu

Lei Wang

Bin Zhu

Wen Xie

Cong Zhao

Yao Zhou

Caiping Ren

Hui Liu

Xingjun Jiang

机构：

[1] Central South University,Cancer Research Institute, Department of Neurosurgery, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital

[2] Changsha Kexin Cancer Hospital,The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, School of Basic Medicine

[3] Central South University,School of Ophthalmology and Optometry and Eye Hospital

[4] Wenzhou Medical University,Department of Neurosurgery, Xiangya Hospital

[5] Central South University,undefined

来源：

Stem Cell Research & Therapy | / 13卷

关键词：

COVID-19; SARS-CoV-2; Stem cell threapy; MSCs; Organoid models;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory coronavirus 2 is currently spreading throughout the world with a high rate of infection and mortality and poses a huge threat to global public health. COVID-19 primarily manifests as hypoxic respiratory failure and acute respiratory distress syndrome, which can lead to multiple organ failure. Despite advances in the supportive care approaches, there is still a lack of clinically effective therapies, and there is an urgent need to develop novel strategies to fight this disease. Currently, stem cell therapy and stem cell-derived organoid models have received extensive attention as a new treatment and research method for COVID-19. Here, we discuss how stem cells play a role in the battle against COVID-19 and present a systematic review and prospective of the study on stem cell treatment and organoid models of COVID-19, which provides a reference for the effective control of the COVID-19 pandemic worldwide.

引用

共 586 条

[1]

Wang C(2020)A novel coronavirus outbreak of global health concern Lancet 395 470-473

[2]

Horby PW(2020)The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China Int J Infect Dis 91 264-266

[3]

Hayden FG(2020)A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Lancet 395 514-523

[4]

Gao GF(2020)SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview Infez Med 28 174-184

[5]

Hui DS(2020)COVID-19 update: The race to therapeutic development Drug Resist Updat 53 179-152

[6]

Azhar EI(2020)Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant J Transl Med 18 192-555

[7]

Madani TA(2020)Emergence of genomic diversity and recurrent mutations in SARS-CoV-2 Infect Genet Evol 83 144-502

[8]

Ntoumi F(2020)Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury Stem Cell Res Ther 11 544-23

[9]

Kock R(2021)Stem cells therapy as a possible therapeutic option in treating COVID-19 patients Stem Cell Rev Rep 17 490-236

[10]

Dar O(2013)Interspecies transmission and emergence of novel viruses: lessons from bats and birds Trends Microbiol 21 12-277

← 1 2 3 4 5 6 7 8 9 10 →